Figure S5. RT-PCR analysis of ALK, RET, or ROS1 fusion in 4 tumor tissues. The mRNA expression of variant 1, 2, 3a, or 3b of EML4-ALK (a), KIF5B-RET, CCDC6-RET (b) or SLC34A2-ROS1 (c) was determined by RT-PCR using the Taqman probes shown in Additional file 1: Table S1. Red lines show fusion geneâpositive tumor tissue, and green lines show fusion geneânegative tumor tissue (PPTX 122 kb
Abstract Background Genetic alterations, including mutation of epidermal growth factor receptor or v...
Association of ALK fusion and the main clinico-pathological and molecular features. Summary of the m...
Recurrent gene fusions in epithelial cancers. Summary of recurrent gene fusions in epithelial carcin...
Figure S1. RT-PCR analysis of ALK, RET, or ROS1 fusion in 37 cancer cell lines. The mRNA expression ...
Figure S6. Summary of ALK, RET, or ROS1 fusion in 4 tumor tissue specimens. Plot of normalized value...
Figure S2. Summary of ALK, RET, or ROS1 fusion in 37 cancer cell lines. Plot of normalized values ca...
Figure S10. Western blotting analysis in a cancer cell line with ROS1 fusion. Cell lysates were harv...
Figure S11. Western blotting analysis in five cancer cell lines without any fusion gene. Cell lysate...
Figure S9. Western blotting analysis in three cancer cell lines with or without RET fusion. Cell lys...
Figure S4. Comparison of molecular weights between wild-type and fusion protein. After high exposure...
Figure S7. Analysis by IHC and FISH of ALK in ILS31007 tissue specimen. The FFPE specimens with tumo...
Table S1. RT-PCR Targets within the Ion AmpliSeq™ Lung Fusion Research Panel. A list of all targets ...
Volcano plots showed differential expression between MAML2 TAD shRNA and control groups in fusion-ne...
Table S1. RNA-sequencing results for tumor tissue (a) or non-malignant lung tissue (b). Differential...
The IHC staining patterns of ROS1 rearrangement cases and non-rearrangement cases. (ZIP 7.10 mb
Abstract Background Genetic alterations, including mutation of epidermal growth factor receptor or v...
Association of ALK fusion and the main clinico-pathological and molecular features. Summary of the m...
Recurrent gene fusions in epithelial cancers. Summary of recurrent gene fusions in epithelial carcin...
Figure S1. RT-PCR analysis of ALK, RET, or ROS1 fusion in 37 cancer cell lines. The mRNA expression ...
Figure S6. Summary of ALK, RET, or ROS1 fusion in 4 tumor tissue specimens. Plot of normalized value...
Figure S2. Summary of ALK, RET, or ROS1 fusion in 37 cancer cell lines. Plot of normalized values ca...
Figure S10. Western blotting analysis in a cancer cell line with ROS1 fusion. Cell lysates were harv...
Figure S11. Western blotting analysis in five cancer cell lines without any fusion gene. Cell lysate...
Figure S9. Western blotting analysis in three cancer cell lines with or without RET fusion. Cell lys...
Figure S4. Comparison of molecular weights between wild-type and fusion protein. After high exposure...
Figure S7. Analysis by IHC and FISH of ALK in ILS31007 tissue specimen. The FFPE specimens with tumo...
Table S1. RT-PCR Targets within the Ion AmpliSeq™ Lung Fusion Research Panel. A list of all targets ...
Volcano plots showed differential expression between MAML2 TAD shRNA and control groups in fusion-ne...
Table S1. RNA-sequencing results for tumor tissue (a) or non-malignant lung tissue (b). Differential...
The IHC staining patterns of ROS1 rearrangement cases and non-rearrangement cases. (ZIP 7.10 mb
Abstract Background Genetic alterations, including mutation of epidermal growth factor receptor or v...
Association of ALK fusion and the main clinico-pathological and molecular features. Summary of the m...
Recurrent gene fusions in epithelial cancers. Summary of recurrent gene fusions in epithelial carcin...